ANU的澳大利亚研究人员确认免疫蛋白NLRC4是肠癌的潜在生物标志和治疗。 Australian researchers at ANU identify immune protein NLRC4 as a potential biomarker and treatment for bowel cancer.

澳大利亚国立大学(ANU)的澳大利亚研究人员已经确定了一种免疫蛋白,NLRC4,这可能有助于发展新的肠癌治疗。 Australian researchers at the Australian National University (ANU) have identified an immune protein, NLRC4, that may aid in developing new bowel cancer treatments. NLRC4可以修复受损的DNA,防止健康的细胞变成癌症。 NLRC4 can repair damaged DNA, preventing healthy cells from becoming cancerous. 它在肠道癌症患者中的存在减少,表明它可以作为预测结果的生物标志。 Its reduced presence in bowel cancer patients suggests it could serve as a biomarker for predicting outcomes. 及早发现肠癌至关重要,因为近99%的病例在早期诊断后可以治疗。 Early detection of bowel cancer is vital, as nearly 99% of cases are treatable when diagnosed early.